Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Maplight Therapeutics › T. Rowe Price Investment Management, Inc. cut its MPLT stake below 5% Fund moves
Why it stands out The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Nov 16, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0001897612-26-000762
Data quality Verified: identifiers matched exactly The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Aug 3, 2026 Insider Officer sold ~$277K of MPLT shares in the open market Aug 13, 2026 Company filing · Form 8-K · Material agreement, Results Signed an important agreement, and reported its results (and 2 more items) Aug 14, 2026 Insider 10% owner purchased ~$50.1M of MPLT shares in the open market Sep 16, 2026 Insider Officer sold ~$193K of MPLT shares in the open market What came next Oct 15, 2026 Insider · 6 people Insiders: 6 sales (~$1.1M) Nov 16, 2026 Company filing · Form 8-K · Results, Reg FD Reported its results, and shared information with investors Nov 16, 2026 Company filing · Form 8-K · Material agreement Signed an important agreement Nov 16, 2026 5% stake Forbion Growth Opportunities Fund III Cooperatief U.A. reported a passive stake (13G) of 8.4%